Practices
- BANKING AND FINANCE
- Acquisition Financings
- Asset-Based Lending
- Bank Mergers and Acquisitions
- Bank Regulatory and Administrative Law Issues
- Entertainment and Film Production Financings
- Financial Institutions Group
- Investment Company Financings
- Mezzanine Lending
- Middle Market Lending
- Securities and Corporate Finance
- Securitizations
- Syndicated Lending
- Tax-Exempt Bond Financing
- CORPORATE
- INVESTMENT MANAGEMENT GROUP
Education
- J.D., Washington & Lee University School of Law, 1979
- B.A., Princeton University, 1975
Bar Admissions
- New York (1980)
- Virginia (1979)
News
- Partner Lawrence Remmel Speaks To New York Times About Mortgage Crisis Residuals at Bank of America and Citi
- Partner Lawrence Remmel Interviewed About Bank of America, Fannie Mae Settlement
- Pryor Cashman Represents Marina Biotech, Inc. in License Agreement with Novartis
- Pryor Cashman Represents East West Bank in Secured Financing of Ultimate Financial Solutions LLC
- Pryor Cashman Represents Marina Biotech, Inc. in Licensing Agreement With Monsanto Company
- Pryor Cashman Represents Marina Biotech, Inc. in $5M Private Placement
- Partner Lawrence Remmel Interviewed About Barney Frank Retirement
- Partner Lawrence Remmel Interviewed About Justice Department Banking Probe
- Partner Lawrence Remmel Interviewed About DOJ Review of Banks Charging Debit Card Fees
- Partner Lawrence Remmel Interviewed About Securitization of Pharmaceutical Royalty Rights
- Partner Lawrence Remmel Speaks to TheStreet.Com About Bank of America Mortgage Woes
- Partner Lawrence Remmel Interviewed About Compliance Duties in Community Banks
- Partner Lawrence Remmel Interviewed About Recent NCUA Suits Against J.P. Morgan and RBS
- Pryor Cashman Represents Marina Biotech, Inc. in Firm Commitment Underwritten Public Offering
- Partner Lawrence Remmel Interviewed About Strength of Corporate Credit Unions
- Partner Lawrence Remmel Interviewed About Credit Unions and Banks
- Pryor Cashman Represents Marina Biotech, Inc. in Firm Commitment Underwritten Public Offering
- Partner Lawrence Remmel Quoted in New York Times Story About Wells Fargo
- Pryor Cashman Represents Marina Biotech, Inc. in Registered Direct Offering
- Pryor Cashman Client Marina Biotech, Inc. Acquires SMARTICLES® Intellectual Property
- Pryor Cashman Client Marina Biotech, Inc. Acquires Cequent Pharmaceuticals, Inc.
- Partner Lawrence Remmel Speaks to Risk and Compliance Group About Dodd-Frank Financial Reform
- Pryor Cashman Client MDRNA, Inc. to Acquire Cequent Pharmaceuticals
- Pryor Cashman Represents MDRNA, Inc. in Registered Direct Offering of Common Stock and Warrants
- Partner Lawrence Remmel Speaks to US Banker About Emerging Market Woes
- Pryor Cashman Team Closes Biotechnology Financing
- Pryor Cashman Represents JP Morgan Chase Bank, N.A. in Redemption Facility Closing
- Pryor Cashman is First to Close International Investment Company Redemption Financing
- Pryor Cashman Represented Purchaser in Biggest NYC Commercial Property Sale of 2007
- Pryor Cashman Closes $1.8 Billion Record-Size Office Building Transaction in Record Time
- Pryor Cashman Assists Biotechnology Investment Company in Formation and Investments
- Pryor Cashman Represents Nastech Pharmaceuticals in Drug Development Deal with Amylin Pharmaceuticals
- Pryor Cashman Negotiates Supply Agreement Between Nastech Pharmaceuticals and Procter & Gamble
- Pryor Cashman Represents Nastech Pharmaceutical in Business Expansion Transactions
Attorneys
Lawrence Remmel
Partnerlremmel@pryorcashman.com
New York, NY 10036-6569
Lawrence Remmel is experienced in banking and real estate financings, 1940 Act transactions, and asset securitizations, including securitizations involving the biotechnology industry. His work frequently involves intellectual property and licensing issues, in particular in the biotechnology area. Larry has worked on warehouse facilities, joint ventures, intellectual property transfers and the merger and acquisition of various businesses. He has been a partner at the firm since 1988.
Larry’s representative transactions include:
- Representation of the sole lender in a $85MM facility to a pool of real estate assets, issued by US and non-US issuers
- Development of Securitized Unregistered Bio-Technology Limited Enhanced™ units, a novel means of securitizing pharmaceutical royalty cash flows
- The Bel Air film financing, providing off-balance sheet studio financing for a renewable slate of films
- Formation of the New Ventures Fund I biotech private equity fund, providing funding to late stage biotechnology companies
Larry provides counsel to JPMorgan Chase Bank N.A. and other institutions on Investment Company Act of 1940 transactions. In addition, he regularly works with Marina Biotech, Inc., various other biotechnology and cosmeceutical companies, and various private equity funds. He also lectures from time to time at JPMorgan Chase and other institutions on the 1940 Act. He is a director of Atossa Genetics Inc., a NASDAQ-listed company (NASDAQ: ATOS), and serves on the company’s audit committee.
Larry is frequently called upon by the press to comment upon banking and finance matters. To read samples of such press coverage, please click here.
Previous Positions
- Reboul, MacMurray, Hewitt, Maynard & Kristol, Associate (1984-88)
- Carter, Ledyard & Milburn, Associate (1979-84)
Speaking Engagements
- Speaker, Secured Transactions: Comparing the Approaches of UCC articles 8 & 9 to the Talmudic Concept of "Shibud," Institute of American and Talmudic Law (April 2013)
- Speaker, Dodd-Frank Financial Reform: Creating a Future of Periodic Failure, RSM McGladrey, Inc. Risk and Compliance Breakfast (July 2010)
- Panelist, Jefferies Life Sciences Conference on Structuring Biotech Licenses (June 2006)
Professional Affiliations
- New York State Bar Association
